The immunomodulatory role of angiocidin, a novel angiogenesis inhibitor

Current Pharmaceutical Design

Volumn 15, Issue 17, 2009, Pages 1937-1948

  Gaurnier Hausser, A ^a   Tuszynski, G P ^b  

^a UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^b Temple University   (United States)

Author keywords

Adjuvant; Angiocidin; Angiogenesis; Cancer; Cytokine; Immunotherapy; Macrophages

Indexed keywords

ALPHA INTERFERON; ANGIOCIDIN; ANGIOGENESIS INHIBITOR; CD69 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; POLYUBIQUITIN; PROTEASOME; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL ADHESION; CELL DIFFERENTIATION; CYTOTOXIC T LYMPHOCYTE; DRUG RECEPTOR BINDING; EXTRACELLULAR MATRIX; HUMAN; IMMUNOMODULATION; LEUKEMIA CELL; LEWIS CARCINOMA; LYMPHOCYTE ACTIVATION; MACROPHAGE; MICROENVIRONMENT; MONOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEINASE INHIBITION; REVIEW; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANGIOGENESIS INHIBITORS; ANTIGEN PRESENTATION; CARRIER PROTEINS; CELL DIFFERENTIATION; CYTOKINES; HUMANS; MACROPHAGES; MONOCYTES; PHAGOCYTOSIS; SIGNAL TRANSDUCTION;

EID: 68449095634     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788453149     Document Type: Review

References (101)

1. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77: 1303-10
2. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998; 58: 3491-4.
3. Schumacher K, Haensch W, Roefzaad C, Schlag PM. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001; 61: 3932-6.
4. Zhang L, Katsaros D, Massobrio M, Makrigiannakis A, Schlienger K, Rubin S. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-13.
5. Maki R. Future directions for immunotherapeutic intervention against sarcomas. Curr Opin Oncol 2006; 18: 363-8.
6. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-8.
7. Diefenbach A, Raulet DH. The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev 2002; 188:9-21
8. Tagawa M. Cytokine therapy for cancer. Curr Pharm Des 2000; 6: 681-99.
9. Nair SK, Morse M, Boczkowski D, Cummings RI, Vasovic L, Gilboa E, et al. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 2002; 235:540-9.
10. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-55.
11. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7
12. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: Implications for new anticancer therapies. J Pathol 2002; 196: 254-65.
13. Andreesen R, Hennemann B, Krause SW. Adoptive immunotherapy of cancer using monocyte-derived macrophages: Rationale, current status, and perspectives. J Leukoc Biol 1998 64: 419-26.
14. Brigati C, Noonan DM, Albini A, Benelli R. Tumors and inflammatory infiltrates: Friends or foes? Clin Exp Metastasis 2002; 19:247-58.
15. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. The origin and function of tumor-associated macrophages. Immunol Today 1992; 13: 265-70.
16. Williams MA, Kelsey SM, Newland AC. GM-CSF and stimulation of monocyte/ macrophage function: in vivo relevance and in vitro observations. Eur J Can 1999 35: S18-S22.
17. Decker T, Lohmann-Matthes ML, Gifford G. Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages. J Immunol 1987; 138: 957-62.
18. Street SE, Cretney E, Smyth MJ. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 2001; 97: 192-7.
19. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004; 4: 11-22.
20. Blattman JN, Greenberg PD. Cancer immunotherapy: A treatment for the masses. Science 2004; 305: 200-5.
21. Gross S, Walden P. Immunosuppressive mechanisms in human tumors: Why we still cannot cure cancer. Immunol Lett 2008; 116: 7-14.
22. Steinman RM, Mellman I. Immunotherapy: Bewitched, bothered, and bewildered no more. Science 2004; 305: 197-200.
23. Parmiani G, Rivoltini L, Andreola G, Carrabba M. Cytokines in cancer therapy. Immunol Lett 2000; 74: 41-4.
24. Cheever M. Twelve immunotherapy drugs that could cure cancer. Immuno Rev 2008; 222: 357-68.
25. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-43.
26. Giovarelli M, Musiani P, Modesti A, Dellabona P, Casorati G, Allione A, et al. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J Immunol 1995; 155: 3112- 23.
27. Kikuchi T, Joki T, Saitoh S, Hata Y, Abe T, Kato N, et al. Antitumor activity of interleukin-2-producing tumor cells and recombinant interleukin 12 against mouse glioma cells located in the central nervous system. Int J Cancer 1999; 80:425-30.
28. Salgia R, Lynch T, Skarin A, Kucca J, Lynch C, Jung K, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 2003; 21: 624-30.
29. Cavallo F, Signorelli P, Giovarelli M, Musiani P, Modesti A, Brunda MJ, et al. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst 1997; 89: 1049-58.
30. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172: 1217- 24.
31. Giezeman-Smits KM, Okada H, Brissette-Storkus CS, Villa LA, Attanucci J, Lotze MT, et al. Cytokine gene therapy of gliomas: Induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity. Cancer Res 2000; 60: 2449-57.
32. Mach N, Dranoff G. Cytokine-secreting tumor cell vaccines. Curr Opin Immunol 2000; 12:571-5.
33. King J, Waxman J, Stauss H. Advances in tumor immunotherapy. QJM 2008; 101(9): 675-83.
34. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994; 86: 1159-66.
35. Rosenberg SA, Restifo N, Yang J, Morgan R, Dudley M. Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8: 299-08.
36. Gough MJ, Melcher AA, Ahmed A, Crittenden MR, Riddle DS, Linardakis E, et al. Macrophages orchestrate the immune response to tumor cell death. Cancer Res 2001; 61: 7240-47.
37. Tsung K, Dolan JP, Tsung YL, Norton JA. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Res 2002; 62:5069-75.
38. Nesbit M, Schaider H, Miller TH, Herlyn M. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol 2001; 166: 6483-90.
39. Hennemann B, Beckmann G, Eichelmann A, Rehm A, Andreesen R. Phase I clinical trial of adoptive immunotherapy of cancer patients using monocyte-derived macrophages activated with interferon γ and lipopolysaccharide. Cancer Immunol Immunother 1998; 45: 250-6.
40. Andreesen R, Scheibenbogen C, Brugger W, Krause S, Meerpohl HG, Leser HG, et al. Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: A new approach to cancer immunotherapy. Cancer Res 1990; 50: 7450-6.
41. Pejawar-Gaddy S, Finn OJ. Cancer vaccines: Accomplishments and challenges. Crit Rev Oncol Hematol 2008; 67: 93-102.
42. Andersen MH, Sorensen RB, Schrama D, Svane IM, Becker JC, Straten PT. Cancer treatment: The combination of vaccination with other therapies. Cancer Immunol Immunother 2008; 57: 1735-43.
43. Sorensen MR, Thomsen AR. Virus-based immunotherapy of cancer: What do we know and where are we going? APMIS 2007; 115: 1177-93.
44. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-39.
45. Griffioen A. Anti-angiogenesis: Making the tumor vulnerable to the immune system. Cancer Immunol Immunother 2008; 57(10): 1553- 8.
46. Tuszynski GP, Rothman VL, Papale M, Hamilton BK, Eyal J. Identification and characterization of a tumor cell receptor for CSVTCG, a thrombospondin adhesive domain. J Cell Biol 1993; 120: 513-21.
47. Tuszynski GP, Nicosia RF. Localization of thrombospondin and its cysteine-serine-valine-threonine-cysteine-glycine-specific receptor in human breast carcinoma. Lab Invest 1994; 70: 228-33.
48. Arnoletti JP, Albo D, Jhala N, Granick MS, Solomon MP, Atkinson B, et al. Computer-assisted image analysis of tumor sections for a new thrombospondin receptor. Am J Surg 1994; 168: 433-6.
49. Wakiyama T, Shinohara T, Shirakusa T, John AS, Tuszynski GP. The localization of thrombospondin-1 (TSP-1), cysteine-serinevaline-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer. Histol Histopathol 2001; 16: 345-51.
50. Sabherwal Y, Rothman VL, Poon RT, Tuszynski GP. Clinical significance of serum angiocidin levels in hepatocellular carcinoma. Cancer Lett 2007; 251: 28-35.
51. Zhou J, Rothman VL, Sargiannidou I, Dimitrov S, Qiu C, Smith E, et al. Cloning and characterization of angiocidin, a tumor cell binding protein for thrombospondin-1. J Cell Biochem 2004; 92: 125- 46.
52. Sabherwal Y, Rothman VL, Dimitrov S, L'Heureux DZ, Marcinkiewicz C, Sharma M, et al. Integrin alpha2beta1 mediates the anti-angiogenic and anti-tumor activities of angiocidin, a novel tumor-associated protein. Exp Cell Res 2006; 312: 2443-53.
53. Liebig C, Agarwal N, Ayala GE, Verstovsek G, Tuszynski GP, Albo D. Angiocidin inhibitory peptides decrease tumor burden in a murine colon cancer model. J Surg Res 2007; 142: 320-6.
54. Wang Q, Young P, Walters KJ. Structure of S5a bound to monoubiquitin provides a model for polyubiquitin recognition. J Mol Biol 2005; 348: 727-39.
55. Lonnroth I, Lange S. Purification and characterization of the antisecretory factor: A protein in the central nervous system and in the gut which inhibits intestinal hypersecretion induced by cholera toxin. Biochim Biophys Acta 1986; 883: 138-44.
56. Dimitrov S, Sabherwal Y, Raymond D, L'Heureux D, Lu Q, and Tuszynski GP. The endothelial apoptotic activity of angiocidin is dependent on its polyubiquitin binding activity. Br J Cancer 2005; 93: 662-69.
57. Voorhees P, Orlowski R. The proteasome and proteasoome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 2006; 46: 189-13.
58. Davidson TS, Hickey WF. Distribution and immunoregulatory properties of antisecretory factor. Lab Invest 2004; 84: 307-19.
59. Kremlev SG, Gaurnier-Hausser A, Del Valle L, Perez-Liz G, Dimitrov S, Tuszynski GP. Angiocidin promotes pro-inflammatory cytokine production and antigen presentation in multiple sclerosis. J Neuroimmunol 2008; 194: 132-42.
60. Gaurnier-Hausser A, Rothman V, Dimitrov S, Tuszynski GP. The novel angiogenic inhibitor, angiocidin, induces differentiation of monocytes to macrophages. Cancer Res 2008; 68: 5905-14.
61. Mehta K, Lopez-Berestein G. Expression of tissue transglutaminase in cultured monocytic leukemia (THP-1) cells during differentiation. Cancer Res 1986; 46: 1388-94.
62. Alessio M, De Monte L, Scirea A, Gruarin P, Tandon NN, Sitia R. Synthesis, processing, and intracellular transport of CD36 during monocytic differentiation. J Biol Chem 1996; 271: 1770-75.
63. Huh HY, Pearce SF, Yesner LM, Schindler JL, Silverstein RL. Regulated expression of CD36 during monocyte-to-macrophage differentiation: potential role of CD36 in foam cell formation. Blood 1996; 87: 2020-28.
64. Pikkarainen T, Brannstrom A, Tryggvason K. Expression of macrophage MARCO receptor induces formation of dendritic plasma membrane processes. J Biol Chem 1999; 274: 10975-82.
65. Vey E, Zhang JH, Dayer JM. IFN-gamma and 1,25(OH)2D3 induce on THP-1 cells distinct patterns of cell surface antigen expression, cytokine production, and responsiveness to contact with activated T cells. J Immunol 1992; 149: 2040-6.
66. Takashiba S, Van Dyke TE, Amar S, Murayama Y, Soskolne AW, Shapira L. Differentiation of monocytes to macrophages primes cells for lipopolysaccharide stimulation via accumulation of cytoplasmic nuclear factor kappaB. Infect Immun 1999; 67: 5573-78.
67. Lysiak JJ, Hussaini IM, Gonias SL. Alpha 2-Macroglobulin synthesis by the human monocytic cell line THP-1 is differentiation state-dependent. J Cell Biochem 1997; 67: 492-7.
68. Soderberg-Naucler C, Fish KN, Nelson JA. Interferon-gamma and tumor necrosis factor-alpha specifically induce formation of cytomegalovirus-permissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines. J Clin Invest 1997; 100: 3154-63.
69. Auwerx J. The human leukemia cell line, THP-1: A multifacetted model for the study of monocyte-macrophage differentiation. Experientia 1991; 47: 22-31.
70. Jimbo K, Park JS, Yokosuka K, Sato K, Nagata K. Positive feedback loop of interleukin-1beta upregulating production of inflammatory mediators in human intervertebral disc cells in vitro. J Neurosurg Spine 2005; 2: 589-95.
71. Araujo F, Slifer T, Li S, Kuver A, Fong L, Remington J. Gemifloxacin inhibits cytokine secretion by lipopolysaccharide stimulated human monocytes at the post-transcriptional level. Clin Microbiol Infect 2004; 10: 213-19.
72. Micouin A, Rouillard D, Bauvois B. Induction of macrophagic differentiation and cytokine secretion by IgG1 molecules in human normal monocytes and myelogenous leukemia cells. Leukemia 1997; 11: 552-60
73. Chiu CP, Lee F. IL-6 is a differentiation factor for M1 and WEHI-3B myeloid leukemic cells. J Immunol 1989; 142: 1909-15.
74. Shabo Y, Lotem J, Rubinstein M, Revel M, Clark SC, Wolf SF, et al. The myeloid blood cell differentiation-inducing protein MGI-2A is interleukin-6. Blood 1988; 72: 2070-73.
75. Takeda K, Akira S. STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev 2000; 11: 199-7.
76. Ihle JN. The Stat family in cytokine signaling. Curr Opin Cell Biol 2001; 13: 211-17.
77. Lodige I, Marg A, Wiesner B, Malecova B, Oelgeschlager T, Vinkemeier U. Nuclear export determines the cytokine sensitivity of STAT transcription factors. J Biol Chem 2005; 280: 43087-99.
78. Lang R. Tuning of macrophage responses by Stat3-inducing cytokines: molecular mechanisms and consequences in infection. Immunobiology 2005; 210: 63-76.
79. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci 2004; 117: 1281-3.
80. Reyes L, Davidson MK, Thomas LC, Davis JK. Effects of Mycoplasma fermentans incognitus on differentiation of THP-1 cells. Infect Immun 1999; 67: 3188-92.
81. Munn DH, Cheung NK. Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony-stimulating factor. J Exp Med 1990; 172: 231-7.
82. Munn DH, Cheung NK. Antibody-independent phagocytosis of tumor cells by human monocyte-derived macrophages cultured in recombinant macrophage colony-stimulating factor. Cancer Immunol Immunother 1995; 41: 46-52.
83. Munn DH, McBride M, Cheung NK. Role of low-affinity Fc receptors in antibody-dependent tumor cell phagocytosis by human monocyte-derived macrophages. Cancer Res 1991; 51: 1117-23.
84. Rao KM. MAP kinase activation in macrophages. J Leukoc Biol 2001; 69: 3-10.
85. Blackwell TS, Christman JW. The role of nuclear factor-kappa B in cytokine gene regulation. Am J Respir Cell Mol Biol 1997; 17: 3-9.
86. Zhou HR, Islam Z, Pestka JJ. Rapid, sequential activation of mitogen-activated protein kinases and transcription factors precedes proinflammatory cytokine mRNA expression in spleens of mice exposed to the trichothecene vomitoxin. Toxicol Sci 2003; 72: 130- 42.
87. Hedges JC, Singer CA, Gerthoffer WT. Mitogen-activated protein kinases regulate cytokine gene expression in human airway myocytes. Am J Respir Cell Mol Biol 2000; 23: 86-94.
88. Means TK, Pavlovich RP, Roca D, Vermeulen MW, Fenton MJ. Activation of TNF-alpha transcription utilizes distinct MAP kinase pathways in different macrophage populations. J Leukoc Biol 2000; 67: 885-93.
89. Park JH, Levitt L. Overexpression of mitogen-activated protein kinase (ERK1) enhances T-cell cytokine gene expression: Role of AP1, NF-AT, and NF-KB. Blood 1993; 82: 2470-77.
90. Zhu W, Downey JS, Gu J, Di Padova F, Gram H, Han J. Regulation of TNF expression by multiple mitogen-activated protein kinase pathways. J Immunol 2000; 164: 6349-58.
91. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annu Rev Immunol 2002; 20: 55-72.
92. Bhattacharyya A, Pathak S, Datta S, Chattopadhyay S, Basu J, Kundu M. Mitogen-activated protein kinases and nuclear factor-kappaB regulate Helicobacter pylori-mediated interleukin-8 release from macrophages. Biochem J 2002; 368: 121-9.
93. Saatian B, Zhao Y, He D, Georas SN, Watkins T, Spannhake EW, et al. Transcriptional regulation of lysophosphatidic acid-induced interleukin-8 expression and secretion by p38 MAPK and JNK in human bronchial epithelial cells. Biochem J 2006; 393: 657-68.
94. Gibbs BF, Grabbe J. Inhibitors of PI 3-kinase and MEK kinase differentially affect mediator secretion from immunologically activated human basophils. J Leukoc Biol 1999; 65: 883-90.
95. Ishizuka T, Chayama K, Takeda K, Hamelmann E, Terada N, Keller GM, et al. Mitogen-activated protein kinase activation through Fc epsilon receptor I and stem cell factor receptor is differentially regulated by phosphatidylinositol 3-kinase and calcineurin in mouse bone marrow-derived mast cells. J Immunol 1999; 162: 2087-94.
96. Kalinina N, Agrotis A, Antropova Y, DiVitto G, Kanellakis P, Kostolias G, et al. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: Role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol 2004; 24: 2320-5.
97. Chandrasekar B, Mummidi S, Perla RP, Bysani S, Dulin NO, Liu F, et al. Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway. Biochem J 2003; 373: 547-58.
98. Gingery A, Bradley E, Shaw A, Oursler MJ. Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFkappaB pathways to maintain osteoclast survival. J Cell Biochem 2003; 89: 165-79.
99. Gustin JA, Ozes ON, Akca H, Pincheira R, Mayo LD, Li Q, et al. Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NFkappa B activation. J Biol Chem 2004; 279: 1615-20.
100. Ouyang W, Li J, Ma Q, Huang C. Essential roles of PI-3K/Akt/IKKbeta/ NFkappaB pathway in cyclin D1 induction by arsenite in JB6 Cl41 cells. Carcinogenesis 2006; 27: 864-73.
101. Schmidt EK, Fichelson S, Feller SM. PI3 kinase is important for Ras, MEK and Erk activation of Epo-stimulated human erythroid progenitors. BMC Biol 2004; 2: 7.